MM-402 is under clinical development by Mind Medicine MindMed and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MM-402’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MM-402 overview
Midomafetamine (MM-402) is under development for the treatment of social anxiety disorder and autism spectrum disorder. The drug candidate is R (-) enantiomer of 3,4-methylenedioxymethamphetamine (MDMA). It acts by targeting monoamine oxidase (MAO), sodium-dependent dopamine transporter (SLC6A3) and sodium-dependent noradrenaline transporter (SLC6A2).
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a pharmaceutical drug development and clinical research company. The company develops medicinal products to treat brain health disorders, psychiatry, pain and substance use disorders, and related therapeutic areas. Its product offerings include psychedelic and empathogen drugs. The company offers research and development supports such as non-clinical, pre-clinical, human clinical trials and investigator-initiated trials. It also develops drugs support clinical data opportunity in autism spectrum disorders (ASD), address a critical gap in opioid use disorder (OUD) treatment. MindMed is headquartered in New York, the US.
For a complete picture of MM-402’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
